WRITE AND COMPLETE APPLICATION Clause Samples

The "Write and Complete Application" clause requires that all information provided in an application, typically for insurance or similar agreements, must be fully and accurately completed by the applicant. This means the applicant is responsible for ensuring that all questions are answered truthfully and no required details are omitted or left blank. By enforcing thorough and honest disclosure, this clause helps prevent misunderstandings or disputes about coverage and ensures that the agreement is based on complete and accurate information.
WRITE AND COMPLETE APPLICATION. ▇▇▇▇▇▇ strongly encourages you to sign up for ▇▇▇▇▇▇.▇▇▇ email notifications regarding this NOFO. If the NOFO is cancelled or modified, individuals who sign up with ▇▇▇▇▇▇.▇▇▇ for updates will be automatically notified.
View SourceView Similar (6)
WRITE AND COMPLETE APPLICATION. After downloading and retrieving the required application components and completing the registration processes, it is time to write and complete your application. With ▇▇▇▇▇▇’s transition to NIH’s eRA grants system, there are new application formatting requirements and validations. All files uploaded with the ▇▇▇▇▇▇.▇▇▇ application MUST be in Adobe PDF file format. Directions for creating PDF files can be found on the ▇▇▇▇▇▇.▇▇▇ website. Please see Appendix B for all application formatting and validation requirements. Applications that do not comply with these requirements will be screened out and will not be reviewed.
View SourceView Similar (3)
WRITE AND COMPLETE APPLICATION. ▇▇▇▇▇▇ strongly encourages you to sign up for ▇▇▇▇▇▇.▇▇▇ email notifications regarding this FOA. If the FOA is cancelled or modified, individuals who sign up with ▇▇▇▇▇▇.▇▇▇ for updates will be automatically notified.
View SourceView Similar (2)
WRITE AND COMPLETE APPLICATION. After downloading and retrieving the required application components and completing the registration processes, it is time to write and complete your application. With ▇▇▇▇▇▇’s transition to NIH’s eRA grants system, there are new application formatting requirements and validations. All files uploaded with the ▇▇▇▇▇▇.▇▇▇ application MUST be in Adobe PDF file format. Directions for creating PDF files can be found on the ▇▇▇▇▇▇.▇▇▇ website. Please see Appendix B for all application formatting and validation requirements. Applications that do not comply with these requirements will be screened out and will not be reviewed. 3.1 Required Application Components Applications must include the following required application components listed in the table below. This table consists of a full list of standard application components, a description of each required component, and its source for application submission. # Standard Application Components Description Source 1 SF-424 (Application for Federal Assistance) Form This form must be completed by applicants for all SAMHSA grants and cooperative agreements. ▇▇▇▇▇▇.▇▇▇ 2 SF-424 A (Budget Information – Non-Construction Programs) Form Use SF-424A. Fill out Sections A, B, D and E of the SF-424A. Section C should only be completed if applicable. It is highly recommended that you use the sample budget format in the FOA. ▇▇▇▇▇▇.▇▇▇ 3 HHS Checklist Form The HHS Checklist ensures that you have obtained the proper signatures, assurances, and certifications. You are not required to complete the entire form, but please include the top portion of the form (“Type of Application”) indicating if this is a new, noncompeting continuation, competing continuation, or supplemental application; the Business Official and Program Director/Project Director/Principal Investigator contact information (Part C); and your organization’s nonprofit status (Part D, if applicable). All SAMHSA Notices of Award (NoAs) will be emailed by ▇▇▇▇▇▇ via NIH’s eRA Commons to the Project Director/Principal Investigator (PD/PI), and Signing Official/Business Official (SO/BO). ▇▇▇▇▇▇.▇▇▇ 4 Project/Performance Site Location(s) Form The purpose of this form is to collect location information on the site(s) where work funded under this grant announcement will be performed. ▇▇▇▇▇▇.▇▇▇ 5 Project Abstract Summary Your total abstract must not be longer than 35 lines. It should include the project name, population(s) to be served (demographics and clinical characteristi...
View SourceView Similar (2)
WRITE AND COMPLETE APPLICATION 
View SourceView Similar (4)

Related to WRITE AND COMPLETE APPLICATION

  • Background and Narrative of Budget Reductions 2. Assumptions Used in the Deficit Reduction Plan: - EBF and Estimated New Tier Funding: - Equal Assessed Valuation and Tax Rates: - Employee Salaries and Benefits: - Short and Long Term Borrowing: - Educational Impact: - Other Assumptions: - Has the district considered shared services or outsourcing (Ex: Transportation, Insurance) If yes please explain:

  • COPIES OF REGULATORY REPORTS AND FILINGS Upon reasonable request, Competitive Supplier shall provide to the Town a copy of each public periodic or incident-related report or record relating to this ESA which it files with any Massachusetts or federal agency regulating rates, service, compliance with environmental laws, or compliance with affirmative action and equal opportunity requirements, unless the Competitive Supplier is required by law or regulation to keep such reports confidential. The Town shall treat any reports and/or filings received from Competitive Supplier as confidential information subject to the terms of Article 16. Competitive Supplier shall be reimbursed its reasonable costs of providing such copies.

  • Check and complete if Transferee will take delivery of a beneficial interest in the IAI Global Note or a Restricted Definitive Note pursuant to any provision of the Securities Act other than Rule 144A or Regulation S. The Transfer is being effected in compliance with the transfer restrictions applicable to beneficial interests in Restricted Global Notes and Restricted Definitive Notes and pursuant to and in accordance with the Securities Act and any applicable blue sky securities laws of any state of the United States, and accordingly the Transferor hereby further certifies that (check one): (a) o such Transfer is being effected pursuant to and in accordance with Rule 144 under the Securities Act; (b) o such Transfer is being effected to the Company or a subsidiary thereof; (c) o such Transfer is being effected pursuant to an effective registration statement under the Securities Act and in compliance with the prospectus delivery requirements of the Securities Act; (d) o such Transfer is being effected to an Institutional Accredited Investor and pursuant to an exemption from the registration requirements of the Securities Act other than Rule 144A, Rule 144, Rule 903 or Rule 904, and the Transferor hereby further certifies that it has not engaged in any general solicitation within the meaning of Regulation D under the Securities Act and the Transfer complies with the transfer restrictions applicable to beneficial interests in a Restricted Global Note or Restricted Definitive Notes and the requirements of the exemption claimed, which certification is supported by (1) a certificate executed by the Transferee in the form of Exhibit D to the Indenture and (2) if such Transfer is in respect of a principal amount of Notes at the time of transfer of less than $250,000, an Opinion of Counsel provided by the Transferor or the Transferee (a copy of which the Transferor has attached to this certification), to the effect that such Transfer is in compliance with the Securities Act. Upon consummation of the proposed transfer in accordance with the terms of the Indenture, the transferred beneficial interest or Definitive Note will be subject to the restrictions on transfer enumerated in the Private Placement Legend printed on the IAI Global Note and/or the Restricted Definitive Notes and in the Indenture and the Securities Act.

  • Complete and Correct Information All information, reports and other papers and data with respect to the Fund furnished to the Purchaser (other than financial information and financial statements, which are covered solely by Section 4.4 of this Agreement) were, at the time the same were so furnished, complete and correct in all material respects. No fact is known to the Fund that materially and adversely affects or in the future may (so far as it can reasonably foresee) materially and adversely affect the MFP Shares, or the Fund’s ability to pay or otherwise perform when due its obligations under this Agreement, any of the MFP Shares and the other Related Documents, that has not been set forth in the Memorandum or in the financial information and other documents referred to in Section 4.4 or this Section 4.8 or in such information, reports, papers and data or otherwise made available or disclosed in writing to the Purchaser. Taken as a whole, the documents furnished and statements made by the Fund in connection with the negotiation, preparation or execution of this Agreement and the other Related Documents do not contain untrue statements of material facts or omit to state material facts necessary to make the statements contained therein, in light of the circumstances under which they were made, not misleading.

  • Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.